期刊文献+

坎地沙坦酯对老年人原发性高血压患者尿微量蛋白排泄的影响 被引量:4

下载PDF
导出
摘要 目的观察坎地沙坦酯对老年人原发性高血压患者尿微量蛋白排泄的影响。方法 选择150例原发性高血压合并微量蛋白尿患者,随机分为2组,观察组76例,给予坎地沙坦酯8~16 mg,每日1次;对照组74例,给予左旋氨氯地平2.5~5 mg,每日1次,治疗8周,观察治疗前及治疗8周后血压及尿微量蛋白值、肾功能变化,并进行比较。结果观察组经坎地沙坦酯治疗8周后,血压降至正常,尿微量蛋白排泄明显减少(P<0.01);对照组血压降至正常,尿微量蛋白排泄下降(P<0.05)。观察组尿微量蛋白排泄量较对照组下降更加明显,差异有统计学意义(P<0.05)。2组均未见明显不良反应。结论坎地沙坦酯有良好的降压疗效,并能有效减少老年人原发性高血压患者尿微量蛋白排泄量,具有肾保护作用。
出处 《疑难病杂志》 CAS 2012年第3期214-215,共2页 Chinese Journal of Difficult and Complicated Cases
  • 相关文献

参考文献9

二级参考文献63

共引文献31

同被引文献35

  • 1钱岳晟,王宪衍,黄高忠,陆凤翔,耿其吉,周和,朱鼎良.坎地沙坦酯片治疗原发性高血压118例[J].中国新药与临床杂志,2005,24(11):849-853. 被引量:11
  • 2Hernandez Hemandez, Sosa Canache B, Velaseo M, et. al, Angiotensin U receptor antonists role in arterial hypertension [ J ]. Hum Hypertens,2002,16 ( suppll ) : s93.
  • 3Nihon Naika Cakkai Zasshi.Candesartan antihypertensive survivalevaluation in japan(CASE-J) trial[J].Ueshima K,2011,100(5):1449-1455.
  • 4Yamaguchi J,Ogawa H,Hagiwara N.Indication and advantage ofcombination therapy with angiotensin II receptor blocker(ARB) andcalcium channel antagonist[J].Nihon Rinsho,2011,69(11):2059-2063.
  • 5Maeda A,Tamura K,Kanaoka T,et al.Combination therapy ofangiotensin II receptor blocker and calcium channel blocker exertspleiotropic therapeutic effects in addition to blood pressure lowering:amlodipine and candesartan trial in Yokohama(ACTY) [JJ.Clin ExpHypertens,2012,34(4):249-257.
  • 6Yasuno S,Fujimoto A,Nakagawa Y,et al.Fixed-dose combinationtherapy of candesartan cilexetil and amlodipine besilate for thetreatment of hypertension in Japan[J],Expert Rev Cardiovasc Ther,2012,10(5):577-583.
  • 7Okura T,Kojima M,Machida H,et al.Effects of up-titration ofcandesartan versus candesartan plus amlodipine on kidney function intype 2 diabetic patients with albuminuria[J].Hum Hypertens,2012,26(4):214-219.
  • 8Matsuno Y,Minatoguchi S,GIFU Substudy Group of The Case-JTrial.Effects of candesartan versus amlodipine on home-measured bloodpressure,QT dispersion and left ventricular hypertrophy in high-riskhypertensive patients[J].Blood Press Suppl? 2011,1(1):12-19.
  • 9Heart Protection Study Collaborative Group. C-reactive protein concentra-tion and the vascular benefits of statin therapy : an analysis of 20 536 pa-tients in the Heart Protection Study[J]. Lancet,2011,377(9764) :469-476.
  • 10Kelly D, Khan S, Cockerill G, et al. Circulating stromelysin-1 ( MMP-3) : a novel predictor of LV dysfunction,remodeling and all-cause mor-tality after acute myocardial infarction[ J]. Eur J Hear Fail, 2008,10?2) : 133-139.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部